Business Wire

Bacardi Expands Its TAILS ® COCKTAILS PROFESSIONAL Range: New Look, New Cocktails, Same Premium Quality

Share

Bacardi, the largest privately held spirits company in the world, has expanded its pioneering TAILS® COCKTAILS PROFESSIONAL range with new cocktails and a new look, available now for the hospitality industry across Western Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005150/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

BACARDI EXPANDS ITS TAILS® COCKTAILS PROFESSIONAL RANGE ACROSS WESTERN EUROPE (Photo: Business Wire)

The premium batched cocktail brand offers the on-trade a hassle-free solution for serving quality cocktails easily, quickly and consistently at scale. Serving a TAILS cocktail takes as little as 15 seconds, and no specialist training is required.

The expanded range of classic and contemporary cocktails, all crafted using the Bacardi portfolio of premium brands has two new additions; the Whisky Sour, made with DEWAR’S® Blended Scotch whisky; and the Rum Punch, made with BACARDĺ® rum.

“Thousands of outlets across Europe are already enjoying a new revenue stream by serving TAILS COCKTAILS PROFESSIONAL, and this year we’re planning to more than double that number – the momentum is huge,” says Evert-Jan Bos, General Manager, TAILS COCKTAILS.

He adds: “With the new flavors, we’re catering for even more tastes and occasions – from summer terraces to cosy winter bars – offering an exciting opportunity for the hospitality industry to tap into the growing demand for cocktails.”

The expanded range also includes the Passion FruitMartini Cocktail and Espresso Martini Cocktail, both made with 42BELOW® vodka; the Gin Garden Cocktail made with BOMBAY® Dry gin and ST-GERMAIN® elderflower liqueur; and the Classic Mojito and Berry Mojito, both made with BACARDĺ rum.

As well as the new-look 1L bottles, there are also three TAILS COCKTAILS PROFESSIONAL 20L kegs - the Passion Fruit Spritz made with 42BELOW® vodka, and the Classic Mojito and Caribbean Punch, both made with BACARDÍ rum – rolling out this summer, allowing outlets to serve cocktails on draught for even quicker, easier service.

With a full live music and events line-up back in Europe this year, Bacardi will also bring high quality cocktails to festivals at scale, with TAILS COCKTAILS PROFESSIONAL at more than 20 of the biggest festivals across the UK, Spain, Belgium and the Netherlands.

The range sits alongside the company’s recent launch of TAILS COCKTAILS, which takes TAILS into the off-trade for the first time, pioneering a new ‘ready-to-shake’ category within cocktails-at-home.

For more information, visit www.tailscocktails.com/professional.

Always drink responsibly

About the TAILS® COCKTAILS PROFESSIONAL range

TAILS COCKTAILS crafts expertly batched cocktails to ensure consistent quality and speed of service throughout the hospitality and events industry. Established in 2010, TAILS COCKTAILS was founded with a vision to make high-quality cocktails more accessible to a wider audience of cocktail lovers. Each TAILS cocktail begins with the highest quality, premium spirits – BACARDI® rum, 42BELOW® vodka, BOMBAY SAPPHIRE® gin, DEWAR’S® Blended Scotch whisky and ST-GERMAIN® elderflower liqueur – blended with top quality ingredients. The range is available in both 1L bottles and 20L kegs with draught pillars. The TAILS COCKTAILS brand is part of the portfolio of Bacardi Limited, headquartered in Hamilton, Bermuda. Visit www.tailscocktails.com/professional.

About Bacardi

Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY® Dry gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded over 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on Twitter, LinkedIn or Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Phillippa Williams, Corporate Communications Manager, Western Europe, Australia & New Zealand, pholmes@bacardi.com
Andrew Carney, Corporate Communications Director, Western Europe, Australia & New Zealand, acarney@bacardi.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p